News
Objective To validate sphingomyelin (SM) dosage in the cerebrospinal fluid (CSF) of patients affected by chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and Guillain-Barré syndrome ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback